Pyrilutamide is a clinical-stage drug being developed by Kintor Pharmaceutical. It is used for treating androgenic alopecia in males. The company also develops other small molecule therapeutics including Proxalutamide (GT0918), KX-826, GT20029, and Destorsertib.
To get more information on pyrilutamide development, purchase our Pyrilutamide LoA Report. It includes drug-specific PTSR and LoA scores, as well as indication benchmarks based on 18 years of historical data.
What is Pyrilutamide?
Pyrilutamide is a topical androgen receptor antagonist. It is a synthetic drug with high affinity for the androgen receptor and acts as a competitive inhibitor of androgen production by blocking the binding site of testosterone to the receptor. It is an alternative to oral 5-alpha reductase inhibitors like finasteride which can cause unwanted side effects such as low libido and erectile dysfunction.
It was recently reported that Kintor Pharmaceutical of China is planning a phase 3 trial for their androgen receptor blocker Buy pyrilutamide Europe in the US next year (2021). This is very exciting news because if successful, pyrilutamide could be an effective alternative to finasteride.
Pyrilutamide is currently in phase II for Androgenic Alopecia. GlobalData tracks the progression of drugs from phase I to phase III, and provides indication benchmark PTSR and LoA scores based on 18 years of historical drug development data. For a detailed analysis of this drug, purchase our Pyrilutamide LoA Report.
Where can I buy Pyrilutamide in Europe?
Pyrilutamide (KX826) is an androgen receptor antagonist that is being developed by Kintor Pharmaceuticals for the treatment of androgenic alopecia. It is currently in phase II clinical trials for this condition in the US and China. The drug has shown a significant improvement in hair density in a small number of patients, but results from the larger phase III trial will give a more accurate picture of its efficacy and safety.
GlobalData tracks phase transition and likelihood of approval metrics to provide a comprehensive drug development view in our Pyrilutamide LoA Report. You can learn more about our reporting methodology and purchase the report here.
What is the price of Pyrilutamide in Europe?
Buy pyrilutamide in Europe is a DHT inhibitor and antiandrogen that has completed phase II clinical trials for the treatment of androgenic alopecia. It has a high binding affinity for the DHT receptor and is capable of inhibiting DHT synthesis and blocking DHT action on scalp hair follicles. It is currently being researched in a large scale, phase III trial by Kintor Pharmaceuticals for the treatment of male pattern baldness. GlobalData has created a drug-specific PTSR and LoA report for Pyrilutamide, based on proprietary data and insights from 18 years of historical drug development. Learn more about this report here.
- Reputable Online Nootropic Vendors: The internet offers numerous online vendors specializing in nootropics and cognitive enhancers. Look for well-established vendors with a track record of quality products and transparent business practices.
- User Reviews: Seek out user reviews and testimonials about the vendor and the Pyrilutamide they provide. Genuine reviews can offer insights into product quality and the vendor’s reliability.
- Quality Assurance: Ensure that the vendor conducts rigorous quality testing on their Pyrilutamide products. Third-party lab testing is a positive sign, as it verifies the purity and potency of the compound.
- Customer Support: Choose a vendor that offers responsive and helpful customer support. Reliable vendors should be willing to address your questions and concerns promptly.
- Dosage Guidance: Pay attention to dosage recommendations provided by the vendor or manufacturer. Start with a low dose and gradually increase as needed while monitoring for any potential side effects.
- Legal Compliance: Be aware of the legal status of Pyrilutamide in your region or country. Ensure that your purchase and use of the compound comply with local regulations.
GlobalData tracks drugs from phase I through commercialization and provides drug-specific PTSR and LoA scores, as well as indication benchmarks derived from 18 years of historical drug development data.